Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026

Same author

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed <i>FLT3</i>-ITD-negative acute myeloid leukemia.

Future oncology (London, England)·2026

Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026

Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

The New England journal of medicine·2026

Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Exploiting cellular pathways to develop new treatment strategies for AML.

Amir T Fathi¹, Steven Grant, Judith E Karp

¹Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, Baltimore, MD 21231, USA. afathi1@jhmi.edu

Cancer Treatment Reviews

|January 9, 2010

Summary

Novel therapies are emerging for acute myeloid leukemia (AML) treatment, offering new hope beyond traditional chemotherapy. These agents target specific molecular pathways, showing promising results in clinical trials for better patient outcomes.

Keywords:

Acute myeloid leukemia FLT3 Flavopiridol HDAC inhibitor PARP Targeted therapies

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Experiment Videos

Last Updated: Jun 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Standard acute myeloid leukemia (AML) treatments using cytarabine and anthracyclines yield poor outcomes, particularly for elderly or high-risk patients.
Emerging research focuses on novel therapeutic agents with diverse mechanisms to overcome limitations of current AML therapies.

Purpose of the Study:

To review preclinical and clinical investigations of promising novel agents for acute myeloid leukemia (AML).
To summarize targeted therapeutics, including kinase inhibitors and oligonucleotide constructs, and other agents like flavopiridol and histone deacetylase inhibitors.

Main Methods:

Review of preclinical and clinical investigations of novel AML therapeutic agents.
Analysis of targeted therapies (e.g., FLT3, BCL2 inhibitors), flavopiridol, and histone deacetylase inhibitors.
Examination of agents used alone and in combination with traditional cytotoxic therapies.

Main Results:

Novel agents target specific molecular pathways crucial for leukemogenesis and proliferation.
Agents like kinase inhibitors, oligonucleotide constructs, flavopiridol, and histone deacetylase inhibitors show potential through various mechanisms.
Early clinical trials indicate encouraging results for these novel therapies in AML treatment.

Conclusions:

Novel therapeutic agents represent a promising advancement in acute myeloid leukemia (AML) treatment.
Targeted therapies and other novel agents offer new strategies to improve outcomes for AML patients.
Ongoing clinical trials are evaluating the efficacy and safety of these agents in AML management.